Skip to content

Psychedelic perceptions: mental health service user attitudes to psilocybin therapy

Kate Corrigan, Maeve Haran, Conor Mccandliss, Róisín M. Mcmanus, Shannon Cleary, Rebecca Trant, Yazeed Kelly, Kathryn Ledden, Gavin Rush, Veronica O’keane, John R. Kelly

Irish Journal of Medical Science (1971 -) June 15, 2021 DOI: 10.1007/s11845-021-02668-2 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Cross-sectional survey Peer reviewed
Sample size 99
Population Mental health service users
Topics Anxiety Psilocybin Psychedelic-assisted therapy
Keywords Mental health Clinical psychology Hallucinogen Perception
Citations 79
Key findings The majority of mental health service users supported further research into psilocybin therapy, with younger age, prior psychedelic experience, and non-religious beliefs associated with more favorable attitudes.

Abstract

Abstract Introduction Despite the rapid advance of psychedelic science and possible translation of psychedelic therapy into the psychiatric clinic, very little is known about mental health service user attitudes.

Objectives: To explore mental health service user attitudes to psychedelics and psilocybin therapy.

Methods: A questionnaire capturing demographics, diagnoses, previous psychedelic and other drug use, and attitudes to psychedelics and psilocybin therapy was distributed to mental health service users.

Results: Ninety-nine participants completed the survey (52% female, mean age 42 years). The majority (72%) supported further research, with 59% supporting psilocybin as a medical treatment. A total of 27% previously used recreational psilocybin, with a male preponderance (p = 0.01). Younger age groups, those with previous psychedelic experience, and those with non-religious beliefs were more likely to have favourable attitudes towards psilocybin. A total of 55% of the total sample would accept as a treatment if doctor recommended, whereas 20% would not. Fewer people with depression/anxiety had used recreational psychedelics (p = 0.03) but were more likely to support government funded studies (p = 0.02). A minority (5%) of people with conditions (psychosis and bipolar disorder) that could be exacerbated by psilocybin thought it would be useful for them. One fifth of the total sample viewed psychedelics as addictive and unsafe even under medical supervision. Concerns included fear of adverse effects, lack of knowledge, insufficient research, illegality, and relapse if medications were discontinued.

Conclusions: The majority supported further research into psilocybin therapy. Younger people, those with previous recreational psychedelic experience, and those with non-religious beliefs were more likely to have favourable attitudes towards psilocybin therapy.

Comparable studies

Other cross-sectional and survey studies on psilocybin for anxiety, most cited first.

Study Year Design Participants
The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms Internet survey respondents reporting challenging experiences with psilocybin 2016 Questionnaire development and validation
Psychedelics and Mental Health: A Population Study Adult population in the United States 2013 Cross-sectional survey n = 130,152
Microdosing psychedelics: Motivations, subjective effects and harm reduction People aged 16 years or older who had used psychedelics and could comprehend written... 2019 Cross-sectional survey n = 525
People of color in North America report improvements in racial trauma and mental health symptoms following psychedelic experiences Black, Indigenous, and people of color (BIPOC) in the US and Canada 2020 Cross-sectional survey n = 313
Naturalistic psilocybin use is associated with persisting improvements in mental health and wellbeing: results from a prospective, longitudinal survey Adults planning to take psilocybin outside clinical research, primarily... 2023 Prospective longitudinal survey n = 2,833

Explore topics

By condition and practice